Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of QL1206 vs Prolia in Healthy Adults
NCT04213105Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area under the plasma concentration-time curve (AUC0-t) at 134 days and Maximum plasma concentration at 134 days. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04213105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213105.